Axon Enterprise (NASDAQ:AXON) CFO Brittany Bagley Sells 870 Shares

Key Points

• Brittany Bagley, CFO of Axon Enterprise, sold 870 shares at an average price of $773.25, totaling approximately $672,727.50, which slightly reduced her stake in the company to 113,022 shares.
• Axon Enterprise's stock saw a 0.6% increase to $760.79, reflecting solid market performance with a market cap of $59.72 billion and a PE ratio of 187.85.
• Analysts have varied opinions on the stock, with price targets ranging from $730 to $1,000, indicating a generally optimistic outlook among several firms.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CFO Brittany Bagley sold 870 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $773.25, for a total transaction of $672,727.50. Following the completion of the sale, the chief financial officer directly owned 113,022 shares of the company's stock, valued at $87,394,261.50. This trade represents a 0.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Axon Enterprise Stock Up 0.6%

NASDAQ:AXON traded up $4.66 during trading hours on Monday, hitting $760.79. The stock had a trading volume of 391,514 shares, compared to its average volume of 683,694. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 1-year low of $376.53 and a 1-year high of $885.91. The business has a 50 day simple moving average of $761.10 and a two-hundred day simple moving average of $688.38. The company has a market cap of $59.72 billion, a PE ratio of 187.85, a price-to-earnings-growth ratio of 27.75 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter last year, the company earned $1.20 earnings per share. Axon Enterprise's revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC lifted its stake in Axon Enterprise by 4.0% in the second quarter. Valeo Financial Advisors LLC now owns 987 shares of the biotechnology company's stock valued at $817,000 after buying an additional 38 shares during the last quarter. Q3 Asset Management bought a new stake in shares of Axon Enterprise during the second quarter valued at about $728,000. Total Investment Management Inc. bought a new stake in shares of Axon Enterprise during the second quarter valued at about $84,000. Orion Porfolio Solutions LLC raised its stake in shares of Axon Enterprise by 23.3% during the second quarter. Orion Porfolio Solutions LLC now owns 4,544 shares of the biotechnology company's stock valued at $3,762,000 after purchasing an additional 858 shares in the last quarter. Finally, Munro Partners bought a new stake in shares of Axon Enterprise during the second quarter valued at about $62,610,000. 79.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AXON. JPMorgan Chase & Co. raised their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research report on Thursday, July 17th. Raymond James Financial reissued an "outperform" rating and set a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Bank of America raised their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Northland Securities set a $800.00 price target on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, Zacks Research downgraded shares of Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 2nd. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $837.69.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.